Phaseline

Companies › Shanghai Miracogen

Shanghai Miracogen: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MRG002
anti-HER2 antibody-drug conjugate
ERBB2Phase 3Advanced or Metastatic Urothelium CancerJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05754853MRG002Phase 3Advanced or Metastatic Urothelium CancerOncologyJan 2027

Targets

ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Companies built like this

Aston Sci. Chengdu SciMount Pharmatech SystImmune DualityBio Greenwich LifeSciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.